The sudden death of 19-year-old law student Josephine Nasr has brought new attention to the risks associated with GLP-1 weight loss medications. Nasr, who was studying at the University of East London, died in her dorm room in September 2025 after taking tirzepatide, a drug sold under brand names like Mounjaro and Zepbound. Her death occurred after she reported symptoms of nausea and vomiting, common side effects of this medication class.
An inquest conducted at the East London Coroner's Court concluded that Nasr died from cardiac arrhythmia. Pathologist Alan Bates noted that Nasr had an undiagnosed congenital heart condition called myocardial bridging, where a coronary artery runs through the heart muscle rather than over it. While this condition is relatively common and often asymptomatic, the pathologist suggested that the drug-induced vomiting likely triggered an electrolyte imbalance, which then resulted in the fatal heart rhythm.
Nasr had been prescribed the medication by a doctor in the United States and was not classified as obese, though she was considered overweight at the time of the prescription. Her family, who grew concerned when they were unable to reach her after her initial complaints of illness, had attempted to send help to her dorm. Despite these efforts, security teams discovered her unresponsive in her bathroom.
This incident highlights the importance of understanding underlying health factors before starting powerful pharmaceutical treatments. As millions of people across the United States and beyond continue to use weight loss drugs like semaglutide and tirzepatide, medical experts continue to track potential side effects. The loss of a young student with a promising future in law serves as a somber reminder to verify individual health risks when using prescribed appetite suppressants.